UroGen Pharma Ltd.
URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase IIIā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$22.80
Price+4.97%
$1.08
1Y
Price
Market Cap
$1.067b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-93.8%
EBITDA Margin-121.3%
Net Profit Margin-154.1%
Free Cash Flow MarginRevenue
$72.301m
-20.0%
1y CAGR+5.9%
3y CAGR+12.9%
5y CAGREarnings
-$114.702m
+9.6%
1y CAGR-2.5%
3y CAGR-1.7%
5y CAGREPS
-$3.46
-16.9%
1y CAGR+8.5%
3y CAGR+7.3%
5y CAGRBook Value
-$115.408m
$185.046m
Assets$300.454m
Liabilities$129.940m
DebtDebt to Assets
70.2%
-1.4x
Debt to EBITDAFree Cash Flow
-$138.125m
-42.3%
1y CAGR-18.8%
3y CAGR-14.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company